CARUMONAM SODIUM

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C12H12N6O10S2.2Na
Molecular Weight	510.367
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].[Na+].NC(=O)OC[C@@H]1[C@H](NC(=O)C(=N/OCC([O-])=O)\C2=CSC(N)=N2)C(=O)N1S([O-])(=O)=O

InChI

InChIKey=BGGXRVPCJUKHTQ-AHCAJXDVSA-L

InChI=1S/C12H14N6O10S2.2Na/c13-11-15-4(3-29-11)7(17-28-2-6(19)20)9(21)16-8-5(1-27-12(14)23)18(10(8)22)30(24,25)26;;/h3,5,8H,1-2H2,(H2,13,15)(H2,14,23)(H,16,21)(H,19,20)(H,24,25,26);;/q;2*+1/p-2/b17-7-;;/t5-,8+;;/m1../s1

HIDE SMILES / InChI

Molecular Formula	C12H12N6O10S2
Molecular Weight	464.388
Charge	-2
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	1
Optical Activity	UNSPECIFIED

Molecular Formula	Na
Molecular Weight	22.98976928
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://211.103.242.133:8080/ziyuan/CDDPdf/med/base/111/%E6%8A%97%E7%94%9F%E7%B4%A0/2320.pdf
Curator's Comment: description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/4073864 | https://www.ncbi.nlm.nih.gov/pubmed/3065522 | https://www.ncbi.nlm.nih.gov/pubmed/3377459

Carumonam is a monobactam antibacterial agent. It was highly active in vitro against members of the family Enterobacteriaceae, Pseudomonas aeruginosa, and Haemophilus influenzae and weakly active against Streptococcus pneumoniae, but it was not active against Staphylococcus aureus. The excellent activity of carumonam against Gram-negative bacteria is related to its high affinity for their penicillin-binding proteins. It is indicated for the treatment of urinary tract infections, chronic respiratory infections, biliary tract infections, peritonitis, sepsis. Another factor that contributes to the excellent activity of carumonam against Gram-negative bacteria is its resistance to beta-lactamases. Adverse effects of the carumonam were limited to phlebitis at the intravenous infusion site; bloody diarrhea.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Bacterial penicillin-binding protein 234 Target ID: CHEMBL2354204 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3928279	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Urinary tract infections 207 Sources: http://211.103.242.133:8080/ziyuan/CDDPdf/med/base/111/%E6%8A%97%E7%94%9F%E7%B4%A0/2320.pdf	Curative	Approved 8583	Amasulin Approved Use It is indicated for the treatment of infections, caused by sensitive bacteria: urinary tract infections, chronic respiratory infections, biliary tract infections, peritonitis, sepsis.
Chronic respiratory infections 2 Sources: http://211.103.242.133:8080/ziyuan/CDDPdf/med/base/111/%E6%8A%97%E7%94%9F%E7%B4%A0/2320.pdf	Curative	Approved 8583	Amasulin Approved Use It is indicated for the treatment of infections, caused by sensitive bacteria: urinary tract infections, chronic respiratory infections, biliary tract infections, peritonitis, sepsis.
Biliary tract infections 2 Sources: http://211.103.242.133:8080/ziyuan/CDDPdf/med/base/111/%E6%8A%97%E7%94%9F%E7%B4%A0/2320.pdf	Curative	Approved 8583	Amasulin Approved Use It is indicated for the treatment of infections, caused by sensitive bacteria: urinary tract infections, chronic respiratory infections, biliary tract infections, peritonitis, sepsis.
Peritonitis 22 Sources: http://www.kmle.co.kr/viewDrug.php?m=%B6%F3%BD%C4&inx=7242&c=4582720816870505d09e6d5a5de7a3fd	Curative	Approved 8583	Amasulin Approved Use It is indicated for the treatment of infections, caused by sensitive bacteria: urinary tract infections, chronic respiratory infections, biliary tract infections, peritonitis, sepsis.
Sepsis 74 Sources: http://www.kmle.co.kr/viewDrug.php?m=%B6%F3%BD%C4&inx=7242&c=4582720816870505d09e6d5a5de7a3fd	Curative	Approved 8583	Amasulin Approved Use It is indicated for the treatment of infections, caused by sensitive bacteria: urinary tract infections, chronic respiratory infections, biliary tract infections, peritonitis, sepsis.

C_max

Value	Dose	Analyte	Population
175 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3364953/	1 g single, intravenous dose: 1 g route of administration: Intravenous experiment type: SINGLE co-administered:	CARUMONAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
192.2 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3364953/	1 g 3 times / day multiple, intravenous dose: 1 g route of administration: Intravenous experiment type: MULTIPLE co-administered:	CARUMONAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
300.7 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3364953/	2 g single, intravenous dose: 2 g route of administration: Intravenous experiment type: SINGLE co-administered:	CARUMONAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
297.7 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3364953/	2 g 3 times / day multiple, intravenous dose: 2 g route of administration: Intravenous experiment type: MULTIPLE co-administered:	CARUMONAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
111 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2745245/	1 g 3 times / day multiple, intravenous dose: 1 g route of administration: Intravenous experiment type: MULTIPLE co-administered:	CARUMONAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
105 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2745245/	1 g 3 times / day multiple, intravenous dose: 1 g route of administration: Intravenous experiment type: MULTIPLE co-administered:	CARUMONAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
214 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2745245/	2 g 3 times / day multiple, intravenous dose: 2 g route of administration: Intravenous experiment type: MULTIPLE co-administered:	CARUMONAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
208 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2745245/	2 g 4 times / day multiple, intravenous dose: 2 g route of administration: Intravenous experiment type: MULTIPLE co-administered:	CARUMONAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
179 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3729324/	1020 mg single, intravenous dose: 1020 mg route of administration: Intravenous experiment type: SINGLE co-administered:		CARUMONAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
493 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3729324/	1040 mg single, intravenous dose: 1040 mg route of administration: Intravenous experiment type: SINGLE co-administered:		CARUMONAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
783 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3729324/	1040 mg single, intravenous dose: 1040 mg route of administration: Intravenous experiment type: SINGLE co-administered:		CARUMONAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1302 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3729324/	1040 mg single, intravenous dose: 1040 mg route of administration: Intravenous experiment type: SINGLE co-administered:		CARUMONAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
56.9 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6395801/	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:		CARUMONAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
113.4 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6395801/	1000 mg single, intravenous dose: 1000 mg route of administration: Intravenous experiment type: SINGLE co-administered:		CARUMONAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
230.4 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6395801/	2000 mg single, intravenous dose: 2000 mg route of administration: Intravenous experiment type: SINGLE co-administered:		CARUMONAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
107.4 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6395801/	1000 mg single, intravenous dose: 1000 mg route of administration: Intravenous experiment type: SINGLE co-administered: PROBENECID	PROBENECID	CARUMONAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
117 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1929242/	1 g single, intravenous dose: 1 g route of administration: Intravenous experiment type: SINGLE co-administered:		CARUMONAM serum	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
186 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1929242/	1 g single, intravenous dose: 1 g route of administration: Intravenous experiment type: SINGLE co-administered:		CARUMONAM serum	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
602 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1929242/	1 g single, intravenous dose: 1 g route of administration: Intravenous experiment type: SINGLE co-administered:		CARUMONAM serum	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1112 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1929242/	1 g single, intravenous dose: 1 g route of administration: Intravenous experiment type: SINGLE co-administered:		CARUMONAM serum	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
186.7 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3364953/	1 g single, intravenous dose: 1 g route of administration: Intravenous experiment type: SINGLE co-administered:		CARUMONAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
156.4 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3364953/	1 g 3 times / day multiple, intravenous dose: 1 g route of administration: Intravenous experiment type: MULTIPLE co-administered:		CARUMONAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
330.6 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3364953/	2 g single, intravenous dose: 2 g route of administration: Intravenous experiment type: SINGLE co-administered:		CARUMONAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
287.7 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3364953/	2 g 3 times / day multiple, intravenous dose: 2 g route of administration: Intravenous experiment type: MULTIPLE co-administered:		CARUMONAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
170 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2745245/	1 g 3 times / day multiple, intravenous dose: 1 g route of administration: Intravenous experiment type: MULTIPLE co-administered:		CARUMONAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
147 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2745245/	1 g 3 times / day multiple, intravenous dose: 1 g route of administration: Intravenous experiment type: MULTIPLE co-administered:		CARUMONAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
300 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2745245/	2 g 3 times / day multiple, intravenous dose: 2 g route of administration: Intravenous experiment type: MULTIPLE co-administered:		CARUMONAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
293 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2745245/	2 g 4 times / day multiple, intravenous dose: 2 g route of administration: Intravenous experiment type: MULTIPLE co-administered:		CARUMONAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
1.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3729324/	1020 mg single, intravenous dose: 1020 mg route of administration: Intravenous experiment type: SINGLE co-administered:		CARUMONAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3729324/	1040 mg single, intravenous dose: 1040 mg route of administration: Intravenous experiment type: SINGLE co-administered:		CARUMONAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
6.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3729324/	1040 mg single, intravenous dose: 1040 mg route of administration: Intravenous experiment type: SINGLE co-administered:		CARUMONAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
11.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3729324/	1040 mg single, intravenous dose: 1040 mg route of administration: Intravenous experiment type: SINGLE co-administered:		CARUMONAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1.76 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6395801/	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:		CARUMONAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1.77 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6395801/	1000 mg single, intravenous dose: 1000 mg route of administration: Intravenous experiment type: SINGLE co-administered:		CARUMONAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1.93 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6395801/	2000 mg single, intravenous dose: 2000 mg route of administration: Intravenous experiment type: SINGLE co-administered:		CARUMONAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1.99 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6395801/	1000 mg single, intravenous dose: 1000 mg route of administration: Intravenous experiment type: SINGLE co-administered: PROBENECID	PROBENECID	CARUMONAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1.53 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1929242/	1 g single, intravenous dose: 1 g route of administration: Intravenous experiment type: SINGLE co-administered:		CARUMONAM serum	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1929242/	1 g single, intravenous dose: 1 g route of administration: Intravenous experiment type: SINGLE co-administered:		CARUMONAM serum	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
5.08 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1929242/	1 g single, intravenous dose: 1 g route of administration: Intravenous experiment type: SINGLE co-administered:		CARUMONAM serum	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
12.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1929242/	1 g single, intravenous dose: 1 g route of administration: Intravenous experiment type: SINGLE co-administered:		CARUMONAM serum	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3364953/	1 g single, intravenous dose: 1 g route of administration: Intravenous experiment type: SINGLE co-administered:		CARUMONAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3364953/	1 g 3 times / day multiple, intravenous dose: 1 g route of administration: Intravenous experiment type: MULTIPLE co-administered:		CARUMONAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3364953/	2 g single, intravenous dose: 2 g route of administration: Intravenous experiment type: SINGLE co-administered:		CARUMONAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3364953/	2 g 3 times / day multiple, intravenous dose: 2 g route of administration: Intravenous experiment type: MULTIPLE co-administered:		CARUMONAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2745245/	1 g 3 times / day multiple, intravenous dose: 1 g route of administration: Intravenous experiment type: MULTIPLE co-administered:		CARUMONAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2745245/	1 g 3 times / day multiple, intravenous dose: 1 g route of administration: Intravenous experiment type: MULTIPLE co-administered:		CARUMONAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2745245/	2 g 3 times / day multiple, intravenous dose: 2 g route of administration: Intravenous experiment type: MULTIPLE co-administered:		CARUMONAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2745245/	2 g 4 times / day multiple, intravenous dose: 2 g route of administration: Intravenous experiment type: MULTIPLE co-administered:		CARUMONAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
0.82% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6395801/			CARUMONAM plasma	Homo sapiens
72% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3364953/			CARUMONAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status:

Doses

Dose	Population	Adverse events
2 g 3 times / day multiple, intravenous Highest studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3364953/	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/3364953/	Sources: https://pubmed.ncbi.nlm.nih.gov/3364953/
1 g 3 times / day multiple, parenteral Studied dose Dose: 1 g, 3 times / day Route: parenteral Route: multiple Dose: 1 g, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3377459/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/3377459/	Sources: https://pubmed.ncbi.nlm.nih.gov/3377459/

PubMed

Title	Date	PubMed
Comparative epileptogenic properties of two monobactam derivatives in C57, Swiss and DBA/2 mice.	1996-09	8889722

Patents

Sample Use Guides

In Vivo Use Guide

The usual dose is 1-2 g daily in two divided doses.

Route of Administration: Other

In Vitro Use Guide

Enterobacteriaceae were highly susceptible to carumonam, 90% of the isolates being inhibited at 0.5 ug/ml.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:54:01 GMT 2025` Edited by `admin` on `Mon Mar 31 17:54:01 GMT 2025`
Record UNII	B4J4M4939D
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CARUMONAM SODIUM

Official Name

English

AMASULIN

Preferred Name

English

AMA 1080

Code

English

RO-172301006

Code

English

ACETIC ACID, (((2-((2-(((AMINOCARBONYL)OXY)METHYL)-4-OXO-1-SULFO-3-AZETIDINYL)AMINO)-1-(2-AMINO-4-THIAZOLYL)-2-OXOETHYLIDEN)AMINO)OXY)-, DISODIUM SALT, (2S-(2.ALPHA.,3.ALPHA.(Z)))-

Systematic Name

English

CARUMONAM SODIUM [JAN]

Common Name

English

CARUMONAM DISODIUM SALT

Common Name

English

Carumonam sodium [WHO-DD]

Common Name

English

AMA-1080

Code

English

RO 17-2301/006

Code

English

CARUMONAM SODIUM [USAN]

Common Name

English

CARUMONAM DISODIUM SALT [MI]

Common Name

English

RO-17-2301/006

Code

English

CARUMONAM SODIUM [MART.]

Common Name

English

(Z)-[[[(2-Amino-4-thiazolyl)[[(2S,3S)-2-(hydroxymethyl)-4-oxo-1-sulfo-3-azetidinyl]carbamoyl]methylene]amino]oxy]acetic acid, carbamate (ester), disodium salt

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C260